--- title: "IBio Names Molly Carr As Chief Medical Officer" type: "News" locale: "en" url: "https://longbridge.com/en/news/294821200.md" description: "iBio, Inc. announced the appointment of Molly Carr as Chief Medical Officer. Carr brings over 30 years of experience in endocrinology and metabolic disease, previously serving as clinical head at Eli Lilly. She will lead global clinical strategy, medical affairs, and regulatory initiatives as iBio advances its obesity and cardiometabolic pipeline. The announcement coincided with a 1.43% rise in iBio shares to $1.42." datetime: "2026-08-04T12:06:48.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294821200.md) - [en](https://longbridge.com/en/news/294821200.md) - [zh-HK](https://longbridge.com/zh-HK/news/294821200.md) generator: "portal-rs" --- # IBio Names Molly Carr As Chief Medical Officer Add as your preferred news source on Google Add Now iBio, Inc. (IBIO), a clinical-stage biotechnology company, on Tuesday announced the appointment of Molly Carr as its chief medical officer. Carr, a physician with more than 30 years of clinical, academic and biopharmaceutical experience in endocrinology and metabolic disease, will lead iBio's global clinical strategy, medical affairs and regulatory initiatives as the company advances its pipeline toward late-stage development. Before joining iBio, Carr held senior roles in clinical development, medical affairs, business development and academia at Eli Lilly and Company, GlaxoSmithKline, CSL Behring, Wyeth, Northwestern University, and the University of Washington. Most recently, she served as clinical head and associate vice president of Eli Lilly's Insulin and Glucagon Franchise, where she oversaw the company's insulin portfolio and clinical development team, including the Phase 3 program for once-weekly insulin candidate efsitora, as well as programs covering prandial insulin, nasal glucagon, biosimilars and legacy insulin products. "Adding Molly to our leadership team is a critical step as we advance our obesity and cardiometabolic pipeline into the clinic, said Martin Brenner," Chief Executive Officer and Chief Scientific Officer of iBio. iBio shares closed up 1.43% at $1.42 on Monday. For comments and feedback contact: editorial@rttnews.com Business News ### Related Stocks - [IBIO.US](https://longbridge.com/en/quote/IBIO.US.md) - [LLY.US](https://longbridge.com/en/quote/LLY.US.md) - [GSK.US](https://longbridge.com/en/quote/GSK.US.md) - [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md) - [CSL.AU](https://longbridge.com/en/quote/CSL.AU.md) - [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md) - [CSLLY.US](https://longbridge.com/en/quote/CSLLY.US.md) ## Related News & Research - [iBio announces annual shareholder meeting](https://longbridge.com/en/news/298071487.md) - [iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update | IBIO Stock News](https://longbridge.com/en/news/297315980.md) - [Revvity agrees to acquire Human Cell Design in metabolic disease research push](https://longbridge.com/en/news/298435704.md) - [Rezolute says FDA review continues for Phase 3 sunRIZE data on ersodetug in congenital hyperinsulinism](https://longbridge.com/en/news/298445417.md) - [Inventiva Highlights Lanifibranor’s Metabolic and Cardiovascular Benefits in MASH](https://longbridge.com/en/news/298363649.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**